Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Collategene Shrinks Ulcers in Buerger's Disease Patients: AnGes MG
April 11, 2011
- Astellas Licenses 3 Compounds to Cardeus
April 11, 2011
- Actos's Use Patent Valid for Combination with α-GIs, SUs, But Not BGs
April 11, 2011
- Mirabegron Improves Key OAB Symptoms in PIII Trial: Astellas
April 11, 2011
- Ono Licenses Cancer Peptide Vaccines from OncoTherapy
April 11, 2011
- Astellas, Pfizer Apply for Additional Indications for Celecox
April 11, 2011
- 5 Remaining Unapproved Drugs/Indications Find Development Sponsors
April 11, 2011
- Wakamoto Aims to Return to Black in FY2011: New President Kamiya
April 11, 2011
- AnGes MG Licenses Transdermal Formulation Technology from MEDRx
April 11, 2011
- Generic Market Share to Reach 6.1% for 2010: Fuji-Keizai
April 11, 2011
- Takeda, DSP Announce Collaboration for Lurasidone in Europe
April 11, 2011
- AXIS Licenses Pilocarpine to Kissei for Development as Fibromyalgia Treatment: SNBL
April 11, 2011
- Prior Assessment Consultation System Started on Full Scale April 1
April 11, 2011
- DSP Licenses Anti-MRSA Drug from Takeda
April 11, 2011
- New Subsidiary in Slovenia to Manage Business in SE Europe: Astellas
April 11, 2011
- AZ Appeals to Tokyo High Court in Iressa Affair
April 11, 2011
- DSP Licenses INT-747 from Intercept
April 11, 2011
- Sandoz K.K. Begins Importing Substitute for Thyradin
April 11, 2011
- JPMA Revises Its Compliance Program GL to Ensure Good Compliance of Group Companies
April 11, 2011
- Eli Lilly Japan Confident about Becoming Top 10 Company by 2020
April 11, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…